BPC-157's gastroprotective properties may reduce these side effects while supporting GI mucosa integrity
A phase 2 trial (SYNERGY-NASH) first demonstrated in vivo that GLP-1RA can achieve histological reversal of hepatic fibrosis in MASLD
95% CI 1.05 to 1.44), with longer treatment periods associated with a greater risk [90]
Its also natural to hope for fast results, especially when social media, coworkers, or friends make it seem like these changes happen overnight
Packaging teams should review pack sizes, resealability, portion architecture and exposure to impulse-led categories before the trend is fully visible in annual sales data
These can include nausea, diarrhea, constipation, or stomach discomfort, especially in the initial stages of treatment